Phosphatidylserine-Targeted Nanotheranostics for Brain Tumor Imaging and Therapeutic Potential

Lulu Wang, MD, PhD1, Amyn A. Habib, MD2,3, Akiva Mintz, MD, PhD4,5, King C. Li, MD4,6, and Dawen Zhao, MD, PhD1,3

Abstract
Phosphatidylserine (PS), the most abundant anionic phospholipid in cell membrane, is strictly confined to the inner leaflet in normal cells. However, this PS asymmetry is found disruptive in many tumor vascular endothelial cells. We discuss the underlying mechanisms for PS asymmetry maintenance in normal cells and its loss in tumor cells. The specificity of PS exposure in tumor vasculature but not normal blood vessels may establish it a useful biomarker for cancer molecular imaging. Indeed, utilizing PS-targeting antibodies, multiple imaging probes have been developed and multimodal imaging data have shown their high tumor-selective targeting in various cancers. There is a critical need for improved diagnosis and therapy for brain tumors. We have recently established PS-targeted nanoplatforms, aiming to enhance delivery of imaging contrast agents across the blood–brain barrier to facilitate imaging of brain tumors. Advantages of using the nanodelivery system, in particular, lipid-based nanocarriers, are discussed here. We also describe our recent research interest in developing PS-targeted nanotheranostics for potential image-guided drug delivery to treat brain tumors.

Keywords
phosphatidylserine (PS), molecular imaging, blood–brain barrier (BBB), brain tumor, nanotheranostics

Mechanisms for Maintenance and Loss of Phosphatidylserine Asymmetry

Asymmetric Distribution of Phosphatidylserine in Normal Cell Membrane

Biological cell membrane is composed of phospholipid bilayer, of which the outer leaflet is formed predominantly with the cholinephospholipids while the anionic aminophospholipids such as phosphatidylserine (PS) are restricted to the inner leaflet.1,2

The asymmetric distribution of PS is maintained by a group of P-type ATPases, known as aminophospholipid translocases, that catalyzes the transport of aminophospholipids from the outer leaflet to the inner leaflet of the plasma membrane against the concentration gradient.2,3 Several Rhesus-associated proteins may also play a role in maintaining the PS asymmetry.2,3

Disruption of PS Asymmetry in Apoptotic or Necrotic Cells

Loss of PS asymmetry, which results in the appearance of PS at the cell surface, occurs often under pathophysiological conditions, that is, apoptosis and necrosis. Accompanying with the influx of Ca2+ into the cytoplasm at the early stage of cell death, the activity of translocase to transport PS inward is inhibited whereas an adenosine triphosphate (ATP)-independent scramblase is activated to disrupt the PS asymmetry by moving

1 Department of Biomedical Engineering, Wake Forest School of Medicine, Winston-Salem, NC, USA
2 Department of Neurology and Neurotherapeutics, University of Texas Southwestern Medical Center, Dallas, TX, USA
3 North Texas VA Medical Center, Dallas, TX, USA
4 Department of Cancer Biology, Wake Forest School of Medicine, Winston-Salem, NC, USA
5 Department of Radiology, Wake Forest School of Medicine, Winston-Salem, NC, USA
6 Clinical and Translational Science Institute, Wake Forest School of Medicine, Winston-Salem, NC, USA

Submitted: 13/01/2017. Revised: 23/03/2017. Accepted: 10/04/2017.

Corresponding Author:
Dawen Zhao, Department of Biomedical Engineering, Wake Forest School of Medicine, Medical Center Boulevard, Winston-Salem, NC 27157, USA.
Email: dawzhao@wakehealth.edu

Creative Commons CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
PS Exposure in Tumor Vascular Endothelial Cells

It has recently been observed that PS becomes exposed on the outer surface of endothelial cells (ECs) in tumor blood vessels, whereas vascular ECs in normal tissues, even in those highly angiogenic ovarian blood vessels during ovulation, lack exposed PS. Although it is not fully understood how and why tumor vascular ECs expose PS to the outer plasma membrane, several factors of characteristic tumor microenvironment are believed to contribute to this phenomenon. Indeed, hypoxia, low pH, and tumor-specific cytokines such as interleukin 1 and tumor necrosis factor (TNF-α) have been correlated with the PS abnormality (Figure 1). In our study, incubation of TNF-α with human vascular umbilical vein cells observed massive PS exposure on the cell surface (unpublished data). These factors may perturb the ATP-dependent translocase activity and/or enhance the ATP-independent scramblase activity to transport PS outward. Importantly, these PS-exposed ECs are viable and not subject to apoptotic process.

Unlike the apoptotic cells, they are not contained by anti-active caspase 3 antibody and can resume growth and reestablish phospholipid asymmetry, which enable them to evade immune surveillance. Examination of large panels of tumor types has found that PS exposure on luminal surface of tumor vasculature is universal despite the extent of exposure that varies between tumors, ranging from about 15% to 50%. In response to cancer treatment such as radiotherapy and/or chemotherapy, significantly increased PS exposures on the tumor vascular ECs.

Phosphatidylserine-Targeting Antibody and Its Mode of Action

Phosphatidylserine-targeting antibodies have been developed by the Thorpe laboratory, including murine antibodies 2aG4 and 3G4 and a chimeric monoclonal antibody bavituximab. The antibodies recognize PS complexed with the PS-binding protein, β2-glycoprotein 1 (β2GP1). The β2GP1 is a 50-kDa glycoprotein that binds weakly to anionic phospholipids under physiological conditions. With the PS antibodies, the binding of β2GP1 to exposed PS is enhanced to form a stable multivalent complex of antibody β2GP1-PS. Since there are abundant β2GP1 in blood, it is unnecessary for in vivo study to have exogenous β2GP1. The PS antibodies are observed to localize to PS-positive blood vessels in multiple tumor models after systemic infusion. Further studies have shown that the PS-bound antibodies induce monocytes to bind to the tumor vasculature and destroy it by antibody-dependent cellular cytotoxicity, leading to tumor growth inhibition. Antitumor effects of these antibodies are enhanced by chemotherapy, radiation, and small molecule tyrosine kinase inhibitor, all of which increase the levels of exposed PS in the tumors and thus amplify the target for attack by the antibodies. More recent studies have suggested that exposed PS suppresses host immunity against tumor cells and PS-targeting antibodies enhance antitumor effect with immune checkpoint cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) or Programmed cell death protein 1 (PD-1) blockade by inducing more CD8+ T cells and fewer immune suppressive myeloid-derived suppressor cells and M2 macrophages.

Bavituximab, the chimeric monoclonal PS-targeting antibody (blood half-life ~ 30 hours), is in advanced clinical trials in patients with lung and breast cancer. More recently, a new, fully human PS-targeting antibody, PGN635, is similar in affinity to bavituximab (Kd ≈ 10^{-10} M). In vitro binding assay has demonstrated its high specificity for the cell-exposing PS. The PS antibodies have a more restricted specificity for PS than does annexin V, known as a PS-binding protein, annexin V also recognizes Phosphatidylethanolamine (PE) in addition to PS and other anionic phospholipids. Moreover, annexin V has a blood half-life of 3 to 7 minutes, which may limit its use for clinical imaging and measuring peak probe uptake responses to therapy. We have exploited F(ab′)2 fragment PGN635 (blood half-life ~ 16 hours) for development of PS-targeted imaging probes and nanoparticles, which will be described in details in the following sections.

Phosphatidylserine-Targeted Molecular Cancer Imaging

In vivo molecular imaging enables visualization of cellular and molecular events in living organisms. Unlike the invasive
pathohistological examination, molecular imaging provides a noninvasive means to assess sensitivity and specificity of disease biomarkers. Various imaging modalities have been applied for evaluation of PS as a cancer biomarker.

Near-Infrared Optical Imaging
Optical imaging is increasingly being used in preclinical cancer research. It is being used in particular to study cancer-specific markers, drug pharmacokinetics, and to monitor drug effects in small animals. The attraction of the technique is that it is inexpensive, simple to conduct, and gives real-time results. In the clinic, optical imaging by visualizing fluorescently labeled tumor cells has recently emerged as an attractive approach to facilitate intraoperative identification of tumor margins or sentinel lymph node metastases. We have thus previously labeled the F(ab')2 fragment of PGN635 with a near-infrared (NIR) dye, IRDye 800CW to image U87 glioma xenografts in a mouse model. Near-infrared optical imaging revealed a clear tumor contrast as early as 4 hours post (intravenous) IV injection of PGN-800CW, which became maximal 24 hours later. Pretreatment of gliomas with a single dose of 6 Gy irradiation to induce increased PS exposure resulted in significantly enhanced tumor contrast. Localization of PGN-800CW to tumors was antigen specific, since an 800CW-labeled control probe of irrelevant specificity did not localize to the tumors. Similarly, Gong et al observed significantly higher uptake of PGN-800CW in docetaxel-treated than nontreated PC3 prostate tumors. Compared to the visible fluorophores, NIR fluorescence penetrates more deeply into tissues, as evidenced in the above study of imaging orthotopic glioma in mice. Clinical applications of optical imaging are currently limited to the detection of tumor margins or deposits during surgery, to the detection of superficial tumors, and to the detection of deep-seated tumors by endoscopy.

Positron Emission Tomography and Single-Photon Emission Computed Tomography Imaging
Both positron emission tomography (PET) and single-photon emission computed tomography (SPECT) are nuclear medicine imaging techniques involving introduction of radioactive tracers into patients and detection of gamma rays emitted directly or indirectly from the tracer. Because of the superb sensitivity and clinical applicability of PET and SPECT imaging, development of radiotracers for cancer imaging has attracted intense interest. Technetium-99m (99mTc, t1/2 ≈6 hours) has been used to label annexin V for SPECT in humans and has shown prognostic value for various cancers. However, to best match the biological half-life of PS-targeting antibody (bavituximab, ~30 hours), those radioisotopes with longer half-life of radioactive decay are preferable. Jennewein et al selected arsenic radioisotope, 74As (β+, t1/2 = 17.8 days) in their study to radionailabel bavituximab for PET imaging of prostate tumors in rats. N-succinimidyl S-acetylhioacetate-modified bavituximab was used to react with arsenic triiodide [AsI3] to achieve stable conjugates. The PET imaging data showed that the prostate tumor-to-liver ratio was 22 for bavituximab compared with 1.5 for an isotype-matched control antibody at 72 hours postinjection. To obtain shorter blood residence times than those required for 74As-bavituximab imaging, Stafford and colleagues chose to use the F(ab')2 fragment of PGN635 (blood half-life ≈16 hours) conjugated with iodine-124, 124I (t1/2 = 4.2 days). Forty-eight hours after injection, PET imaging detected 124I-PGN635 F(ab')2 uptake in the PC3 prostate tumors in mice that was significantly higher than that of the 124I-labeled F(ab')2 of a control antibody. An SPECT imaging radioisotope, indium-111 (111In, t1/2 = 2.8 days), was also used to radionailabel the full-length bavituximab in a study in small cell lung cancer (NSCLC) xenografts. Similar to the PET findings, the SPECT imaging detected a peak uptake (tumor to muscle ratio = 5.2) by the NSCLC tumors at 72 hours post IV injection of 111In-DOTA-bavituximab.

Magnetic Resonance Imaging
Magnetic resonance imaging (MRI) is a commonly used imaging tool for clinical disease diagnosis. Despite its inherently low sensitivity, MRI has high spatial resolution and excellent soft tissue contrast. In comparison to paramagnetic gadolinium-based T1 contrast agents, superparamagnetic iron oxide nanoparticle (SPIO) has much higher molar relaxivity and is thus widely used for molecular MRI applications. We have previously conjugated polyethylene glycol PEGylated SPIO with PGN635 F(ab')2 to evaluate the feasibility of MRI to study its tumor vascular-targeting specificity in 4T1 mouse mammary tumors. Consistent with other imaging modalities, MRI clearly visualized intratumoral signal loss due to specific binding of PGN635 F(ab')-SPIO to tumor vascular ECs. Importantly, MRI provided more detailed information about intratumoral distribution of the nanoprobes, which was determined to colocalize with histological staining of tumor vascular ECs. Unlike the T1-positive contrast, SPIO, the T2 contrast agent SPIO generates negative contrast on T2 or T2*-weighted images. It is noticeable that signal loss due to SPIO shortening of T2 relaxation time is often difficult to differentiate from those low signals induced by B0 inhomogeneity or susceptibility artifacts. To overcome it, we applied the “hot spot” analysis approach in our study, which was found useful to distinguish SPIO-induced signal voids from initial baseline level of dark signals (Figure 2).

Development of PS-Targeted Lipid-Based Nanoplatforms
Rationale for Developing PS-Targeted Liposomal Nanocarrier
Nanoparticles are emerging as promising carriers of drugs or imaging agents because of their advantageous properties such as large payload capacity, prolonged blood circulation time, and protection of the enclosed molecules from interacting with
et al.51 SPIO indicates superparamagnetic iron oxide nanoparticle. nonirradiated or irradiated tumor (arrowhead). Adapted from Zhou in injection of the control antibody conjugates, Aur-SPIO in either a contrast, there was essentially no change in hot spots before and after tumor, the irradiated tumor appeared to have more hot spots. B, In tumors after injection of PGN-SPIO. Compared to the nonirradiated was presented in a representative nonirradiated and irradiated tumor (arrowhead). Increased hot spots were observed in both of the images. A, Baseline level of hot spots prior to injection of PGN-SPIO was presented in a representative nonirradiated and irradiated tumor (arrowhead). Increased hot spots were observed in both of the tumors after injection of PGN-SPIO. Compared to the nonirradiated tumor, the irradiated tumor appeared to have more hot spots. B, In contrast, there was essentially no change in hot spots before and after injection of the control antibody conjugates, Aur-SPIO in either a nonirradiated or irradiated tumor (arrowhead). Adapted from Zhou et al.51 SPIO indicates superparamagnetic iron oxide nanoparticle.

Figure 2. Quantitative “hot spot” analysis of heterogeneous intra-tumoral distribution of PGN635 F(ab)2-SPIO. Hot spots maps were created by identifying hypointense regions in tumor on T2-weighted images and then overlapping them on the corresponding T2-weighted images. A, Baseline level of hot spots prior to injection of PGN-SPIO was presented in a representative nonirradiated and irradiated tumor (arrowhead). Increased hot spots were observed in both of the tumors after injection of PGN-SPIO. Compared to the nonirradiated tumor, the irradiated tumor appeared to have more hot spots. B, In contrast, there was essentially no change in hot spots before and after injection of the control antibody conjugates, Aur-SPIO in either a nonirradiated or irradiated tumor (arrowhead). Adapted from Zhou et al.51 SPIO indicates superparamagnetic iron oxide nanoparticle.

blood components.52-55 Among various types of nanoparticles, lipid-based liposomes and micelles are the most investigated for biomedical applications. Several Federal Drug Administration (FDA)-approved drug preparations utilizing liposomal delivery systems have shown promises in the treatment of various cancer types in clinic. Liposomes are composed of either natural or synthetic amphiphilic lipids. Amphiphilic or hydrophobic molecules can be solubilized in the bilayer, whereas the aqueous core can be loaded with water-soluble biomaterials. We have previously fabricated PS-targeted liposomes (PS-L) by conjugating PGN635 F(ab')2 to distal termini of Polyethylene glycol (PEG) chains.56,57 To prove that the enhanced tumor-targeted imaging can be achieved by the liposomal delivery system, we encapsulated IRDye 800CW to the core of PS-L to conduct optical imaging of gliomas.56 In comparison to the nonliposomal probe, PGN-800CW, the liposomal PS-L-800CW achieved >10-fold increase in tumor contrast by in vivo optical NIR imaging (tumor to normal ratio = 20).56 Accompanied with increased tumor contrast, there was significantly less accumulated PS-L-800CW in the liver and spleen. The large payload of 800CW dye and increased binding affinity owing to multiple surface antibodies per liposome likely contribute to the enhancement.

Another reason behind developing lipid-based nanoparticles for PS-targeted nanodelivery systems is due to their ability to deliver the cargos into cytoplasm. As mentioned above, the mode of action of PS-targeting antibodies is that they bind to β2GP1-PS to form complexes that remain on external cell membrane without entry into the cell, which is evidenced by visualizing the cell membrane-localized complexes by immunofluorescence microscopy. The cell membrane localization was also observed for the conjugates of PS antibodies with fluorescent dyes or metallic SPIO nanoparticles in our studies (Figure 3). Intriguingly, when PS-L loaded with the dye and/or SPIO were incubated with the PS-exposed cells, intracellular localization of the dye or SPIO was clearly seen (Figure 3). Although exact mechanisms accounting for this disparity are not fully clear, it is believed that the cell surface bound PS-L leads to close apposition and subsequent fusion or hemifusion between the lipid layers of liposome and cell membrane and then the release of the cargos into the cytosol. Indeed, others have reported similar findings of other types of lipid-based nanoparticles, targeting cell surface molecules.58-61

PS-Targeted Liposomal Nanoprobes for Brain Tumor Imaging

The most common types of malignant brain tumors in adults are brain metastasis and primary glioblastoma multiforme (GBM), both of which are highly lethal, with a median survival of less than a year.62,63 Existence of blood–brain barrier (BBB) constitutes a critical challenge for accurate diagnosis and effective treatment.64-67 It is well recognized that disruption of the BBB occurs with tumor growth; however, the tumor BBB disruption is incomplete even at the late stage of these malignant brain tumors, which prevents sufficient therapeutic or diagnostic agents from entry in the tumor in brain parenchyma.68,69

Much effort has been made to improve delivery of therapeutic or imaging agents to brain tumors by penetrating the BBB.70-73 Although various strategies have been explored to improve drug permeation into brain tumors via physical or chemical means to manipulate the tumor BBB, limited success has been achieved. Clearly, the discovery of a glioma-specific biomarker will be critical for development of a glioma-targeted nanodelivery system. Ideally, this biomarker needs to be accessible to its ligands or antibodies. Thus, vascular luminal surface-exposed molecules have attracted intense interests.74 A number of endogenous transporters on the surface of the blood vessels are well known for their roles on receptor-mediated transport of large molecules across the BBB. This process is recognized as the receptor-mediated transport. Such receptors as transferrin receptor, low-density lipoprotein receptor, insulin-like growth factor receptor, and nicotinic acetylcholine receptor have been well investigated in functionalizing various nanocarriers, aiming to transport their cargos into brain tumor parenchyma.75-77 Tumor angiogenic factors such as vascular endothelial growth factor and its transmembrane receptor and various integrins have also been extensively explored for developing brain tumor-targeted
nanoplatforms. In particular, a large number of nanocarriers utilizing antibodies or cyclic Arg-Gly-Asp peptides targeting \(\alpha_v\beta_3\) integrin have been convincingly shown to deliver therapeutic or imaging agents to brain tumor tissues.\(^7\) The abovementioned receptors are constitutively expressed on the BBB of normal brain; however, their overexpression on the proliferating tumor ECs could lead to preferential delivery to the brain tumor.

Our published and unpublished studies have investigated PS exposure on tumor vascular ECs of various brain tumor xenografts of the established brain tumor cell lines or patient-derived xenografts (PDX) cells.\(^5\) Unlike the tumor angiogenic markers such as \(\alpha_v\beta_3\) integrin, immunohistological examinations have shown that extensive PS exposure is not only present in the angiogenic tumor vessels but also in those of the infiltrative tumors, but not in the normal brain.\(^2\) This is important for developing brain tumor-targeted therapeutics because the infiltrative tumor cells that often co-opt with non-disruptive, preexisting brain blood vessels account ultimately for cancer recurrence. Thus, PS exposure on the luminal surface of tumor, but not normal blood vessels in the brain, establishes itself a highly specific biomarker for brain tumors. We thus hypothesize that the systemically administered PS-L binds specifically to tumor vascular ECs, becomes subsequently internalized into the cells, and then enables its cargos to be efficiently delivered to brain tumor parenchyma by penetrating the BBB.

To test this, we exploited the PS-L loaded with dual imaging contrast agents: SPIO in the core and NIR dye in the lipid layers for multimodal imaging of human U87 gliomas growing orthotopically in mice.\(^8\) Both in vivo optical imaging and MRI depicted clear tumor contrast, distinct from the surrounding normal brain. Intriguingly, longitudinal MRI revealed temporal and spatial intratumoral distribution of the PS-L by following MRI contrast changes, which appeared punctate in tumor periphery at an earlier time point (4 hours) and became clustering and disseminated throughout the tumor at 24 hours postinjection (Figure 4). The noticeable pattern of punctate MRI signal changes at 4 hours post IV injection may result from the vascular phase of PS-L-IO/DiR when significant numbers of the circulating PS-L-IO/DiR bound to the PS exposed on tumor vascular ECs but not yet penetrated the vessels. The timing of the vascular phase actually coincided well with our previous studies of using PGN635 to localize to exposed PS in tumors, in which our histopathological analysis determined massive PGN635 binding to tumor vascular ECs at 4 hours. Following the vascular phase, the tissue phase was occurring over time after subsequent internalization by ECs and then followed by extravasation through the tumor BBB and extravascular tissue distribution of the PS-L-IO/DiR, which was reflected as the widespread clustering dark signals in both tumor center and periphery on T2-weighted MRI at 24 hours. It is well recognized that the physical features of nanocarriers have significant effects on their intratumoral diffusibility. Nance et al have recently shown that with appropriate PEG coating and a neutral surface charge, the actual size of
nanoparticles can go up to 114 nm without significantly affecting their movement within brain tissues. In our study, the PEGylated PS-L-IO/DiR had a mean size of 110 nm and a surface charge near to 0, which may also contribute to the wide distribution of the PS-L-IO/DiR in glioma.

Phosphatidylserine-Targeted Nanotheranostics for Image-Guided Drug Delivery

It is well recognized that effectiveness of a nanodrug is often governed by the kinetics of drug release and distribution after systemic administration. There is an increasing interest in developing nanotheranostics, an integrated system of imaging agents with anticancer drugs. Ideally, the nanotheranostic system enables the noninvasive in vivo imaging to monitor the nanodrug delivery to not only their targets but also off-target sites. In particular, some potent chemotherapeutic agents are known for their severe toxicity to normal tissues as well.

Arsenic trioxide (ATO) is such an exemplary anticancer drug. Arsenic trioxide is approved by the FDA for the treatment of acute promyelocytic leukemia (PML). Arsenic trioxide has also demonstrated significant activity in treating solid tumors in preclinical studies. Several recent studies have shown that ATO is able to reverse glioblastoma resistance to mechanistic target of rapamycin (mTOR)-targeted therapies by inhibiting PML protein signaling and deplete the cancer stem-like cell population by inhibiting Hedgehog and Notch pathways. However, clinical use of ATO on solid tumors has generally been limited by its systemic cytotoxicity.

Nanoencapsulated ATO within a cancer-targeted nanodelivery system may have a potential to alleviate its damage to healthy tissues. Swindell et al. and Chen et al. have recently shown a successful strategy to utilize transition metals such as nickel or copper to actively load ATO into liposome. Nickel or copper and ATO form a complex in the core of liposome, preventing the leakage of ATO from liposomes. The stability of the complex depends on pH: It is stable at a neutral pH, while it releases the therapeutic As$^{3+}$ at a low pH, that is, pH <6. Utilizing the transition metal approach, we have recently developed a novel nanohybrid of ATO complex with manganese. We chose to use manganese (Mn$^{2+}$) to entrap ATO into liposome because Mn provides paramagnetic MRI contrast. With 5 unpaired electrons, Mn$^{2+}$ is among the best T$_1$ contrast agents. However, the formation of As-Mn precipitates in the core of liposomes possesses magnetic susceptibility effects, resulting in a dark MRI signal. However, after the cell uptake and exposure to the low pH in the endosome-lysosome system, the As-Mn complex decomposes to release ionic As$^{3+}$, the active form of ATO and Mn$^{2+}$, which gives a bright signal on T$_1$-weighted images. Thus, the convertible MRI contrast of Mn can serve as a surrogate of delivery and release of free ATO from its inactive nanoformulation. As for other dual functional nanoformulations, of which imaging probes and drugs are often loaded separately into a different compartment of a nanocarrier, that is, core and shell or surface conjugation via a linker, inconsistent release or leakage of the imaging agents with the drugs could be encountered after administration, which will hinder the imaging-based accurate monitoring of drug distribution. Built into the previously established PS-targeted nanoplateform, the nanoencapsulated ATO enables GBM-targeted delivery while minimizing off-target effects. Our in vitro studies have demonstrated that PS-L-As-Mn effectively kills temozolomide-resistant GBM PDX cells.
Extensive studies are needed to investigate its in vivo specific binding, pH-responsive release kinetics, and ultimately the ability of PS-L-As-Mn to serve as a useful nanotheranostic agent for image-guided delivery of ATO in the GBM PDX models.

Conclusions
In summary, we have demonstrated the utility of PS-targeted liposomal nanoplatfrom for molecular cancer imaging, in particular, brain tumors imaging via its ability to penetrate the tumor BBB. By encapsulating extremely toxic chemotherapeutic agents, that is, ATO, the PS-targeted delivery of ATO specifically to brain tumors may be useful to treat those malignant brain tumors resistant to the current standard of care, while minimizing its systemic side effects. Furthermore, development of PS-targeted nanotheranostics by incorporating imaging contrast agents with anticancer drugs into the same nanostructure may enable image-guided drug delivery to treat brain tumors. Because PS is the same molecule and has the same distribution and regulation in all mammalian species, it is likely that the mouse data will extrapolate to humans. Along with its favorable safety profile, the PS-targeted lipid-based nanoplatform may be expedited for clinical evaluation of its applicability as a nanocarrier of diagnostic and therapeutic agents for patients with brain tumor.

Acknowledgments
The author would like to pay tribute to the late Dr Philip Thorpe for his pioneered research on phosphatidylserine and development of a series of PS-targeting antibodies. The authors thank Peregrine Pharmaceuticals Inc, Tustin, California, for the provision of PGN635 antibody.

Declaration of Conflicting Interests
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: GBM research has been supported in part by NIH R01 CA194578 (DZ), the Wells Fargo Scholar Program (DZ), and the Wake Forest Baptist Comprehensive Cancer Center’s NCI Cancer Center (grant P30CA012197), as well as a grant from the Department of Veteran’s Affairs I01BX002559 (AH). Funding has also come from the Wake Forest Baptist’s NCI Cancer Center’s P30CA012197 (DZ), the Wake Forest Baptist Comprehensive Cancer Center’s NCI Cancer Center (grant P30CA012197) as well as a grant from the Department of Veteran’s Affairs I01BX002559 (AH). The research, authorship, and/or publication of this article: GBM research has been supported in part by NIH R01 CA194578 (DZ), the Wells Fargo Scholar Program (DZ), and the Wake Forest Baptist Comprehensive Cancer Center’s NCI Cancer Center (grant P30CA012197), as well as a grant from the Department of Veteran’s Affairs I01BX002559 (AH).

References
1. Verkleij AJ, Zwaal RF, Roelofsen B, Comfurius P, Kastelijn D, van Deenen LL. The asymmetric distribution of phospholipids in the human red cell membrane. A combined study using phospholipases and freeze-etch electron microscopy. Biochim Biophys Acta. 1973;323(2):178–193.
2. Connor J, Pak CH, Zwaal RF, Schroit AJ. Bidirectional transbilayer movement of phospholipid analogs in human red blood cells. Evidence for an ATP-dependent and protein-mediated process. J Biol Chem. 1992;267(27):19412–19417.
3. Bruckheimer EM, Schroit AJ. Membrane phospholipid asymmetry: host response to the externalization of phosphatidylserine. J Leukoc Biol. 1996;59(2):784–788.
4. Lee SH, Meng XW, Flattner KS, Loegering DA, Kaufmann SH. Phosphatidylserine exposure during apoptosis reflects bidirectional trafficking between plasma membrane and cytoplasm. Cell Death Differ. 2013;20(1):64–76.
5. Schlegel RA, Callahan MK, Williamson P. The central role of phosphatidylserine in the phagocytosis of apoptotic thymocytes. Ann N Y Acad Sci. 2000;926:217–225.
6. Baxter AA, Hulett MD, Poon IK. The phospholipid code: a key component of dying cell recognition, tumor progression and host-microbe interactions. Cell Death Differ. 2015;22(12):1893–1905.
7. Callahan MK, Williamson P, Schlegel RA. Surface expression of phosphatidylserine on macrophages is required for phagocytosis of apoptotic thymocytes. Cell Death Differ. 2000;7(7):645–653.
8. Miyanoishi M, Tada K, Koike M, Uchiyama Y, Kitamura T, Nagata S. Identification of Tim4 as a phosphatidylserine receptor. Nature. 2007;450(7168):435–439.
9. Ran S, Downes A, Thorpe PE. Increased exposure of anionic phospholipids on the surface of tumor blood vessels. Cancer Res. 2002;62(21):6132–6140.
10. Ran S, He J, Huang X, Soares M, Scothorn D, Thorpe PE. Anti-tumor effects of a monoclonal antibody that binds anionic phospholipids on the surface of tumor blood vessels in mice. Clin Cancer Res. 2005;11(4):1551–1562.
11. Ran S, Thorpe PE. Phosphatidylserine is a marker of tumor vasculature and a potential target for cancer imaging and therapy. Int J Radiat Oncol Biol Phys. 2002;54(5):1479–1484.
12. Herrmann A, Devaux PF. Alteration of the aminophospholipid translocase activity during in vivo and artificial aging of human erythrocytes. Biochim Biophys Acta. 1990;1027(1):41–46.
13. Liu J, Epand RF, Durrant D, et al. Role of phospholipid scramblase 3 in the regulation of tumor necrosis factor-alpha-induced apoptosis. Biochemistry. 2008;47(15):4518–4529.
14. Wang H, Joseph JA. Mechanisms of hydrogen peroxide-induced calcium dysregulation in PC12 cells. Free Radic Biol Med. 2000;28(8):1222–1231.
15. Hammill AK, Uhr JW, Scheuermann RH. Annexin V staining due to loss of membrane asymmetry can be reversible and precede commitment to apoptotic death. Exp Cell Res. 1999;251(1):16–21.
16. Mirnikjoo B, Balasubramanian K, Schroit AJ. Mobilization of lysosomal calcium regulates the externalization of phosphatidylserine during apoptosis. J Biol Chem. 2009;284(11):6918–6923.
17. Balasubramanian K, Schroit AJ. Aminophospholipid asymmetry: a matter of life and death. Annu Rev Physiol. 2003;65:701–734.
18. He J, Luster TA, Thorpe PE. Radiation-enhanced vascular targeting of human lung cancers in mice with a monoclonal antibody that binds anionic phospholipids. Cancer Res. 2002;62(21):6132–6140.
19. Cheng X, Li L, Thorpe PE, Yopp AC, Brekken RA, Huang X. Antibody-mediated blockade of phosphatidylserine enhances the antitumor effect of sorafenib in hepatocellular carcinomas xenografts. Ann Surg Oncol. 2016;23(suppl 5):583–591.
20. Thorpe PE. Vascular targeting agents as cancer therapeutics. Clin Cancer Res. 2004;10(2):415–427.
21. He J, Yin Y, Luster TA, Watkins L, Thorpe PE. Antiphosphatidylserine antibody combined with irradiation damages tumor blood vessels and induces tumor immunity in a rat model of glioblastoma. *Clin Cancer Res.* 2009;15(22):6871–6880.

22. Huang X, Bennett M, Thorpe PE. A monoclonal antibody that binds anionic phospholipids on tumor blood vessels enhances the antitumor effect of docetaxel on human breast tumors in mice. *Cancer Res.* 2005;65(10):4408–4416.

23. Tomillero A, Moral MA. Gateways to clinical trials. *Methods Find Exp Clin Pharmacol.* 2009;31(7):661–700.

24. Balasubramanian K, Schroit AJ. Characterization of phosphatidylserine-dependent beta2-glycoprotein I macrophage interactions. Implications for apoptotic cell clearance by phagocytes. *J Biol Chem.* 1998;273(44):29272–29277.

25. Luster TA, He J, Huang X, et al. Plasma protein beta-2-glycoprotein I mediates interaction between the anti-tumor monoclonal antibody 3G4 and anionic phospholipids on endothelial cells. *J Biol Chem.* 2006;281(40):29863–29871.

26. Yin Y, Huang X, Lynn KD, Thorpe PE. Phosphatidylserine-targeting antibody induces M1 macrophage polarization and promotes myeloid-derived suppressor cell differentiation. *Cancer Immunol Res.* 2013;1(4):256–268.

27. Freimark BD, Gong J, Ye D, et al. Antibody-mediated phosphatidylserine blockade enhances the antitumor responses to CTLA-4 and PD-1 antibodies in melanoma. *Cancer Immunol Res.* 2016;4(6):531–540.

28. Gray MJ, Gong J, Hatch MM, et al. Phosphatidylserine-targeting antibodies augment the anti-tumorigenic activity of anti-PD-1 therapy by enhancing immune activation and downregulating pro-oncogenic factors induced by T-cell checkpoint inhibition in murine triple-negative breast cancers. *Breast Cancer Res.* 2016;18(1):50.

29. Birge RB, Boeltz S, Kumar S, et al. Phosphatidylserine is a global immunosuppressive signal in effectorcytosis, infectious disease, and cancer. *Cell Death Differ.* 2016;23(6):962–978.

30. Gerber DE, Stopec AT, Wong L, et al. Phase I safety and pharmacokinetic study of bavituximab, a chimeric phosphatidylserine-targeting monoclonal antibody, in patients with advanced solid tumors. *Clin Cancer Res.* 2011;17(21):6888–6896.

31. Digumarti R, Bapsy PP, Suresh AV, et al. Bavituximab plus paclitaxel and carboplatin for the treatment of advanced non-small-cell lung cancer. *Lung Cancer.* 2014;86(2):231–236.

32. Zhao D, Stafford JH, Zhou H, Thorpe PE. Near-infrared optical imaging of exposed phosphatidylserine in a mouse glioma model. *Transl Oncol.* 2011;4(6):355–364.

33. Stafford JH, Hao G, Best AM, Sun X, Thorpe PE. Highly specific PET imaging of prostate tumors in mice with an iodine-124-labeled antibody fragment that targets phosphatidylserine. *PLoS One.* 2013;8(12):e84864.

34. Gong J, Archer R, Brown M, et al. Measuring response to therapy by near-infrared imaging of tumors using a phosphatidylserine-targeting antibody fragment. *Mol Imaging.* 2013;12(1):244–256.

35. Weissleder R, Pittet MJ. Imaging in the era of molecular oncology. *Nature.* 2008;452(7187):580–589.

36. Pyisz MA, Gambhir SS, Willmann JK. Molecular imaging: current status and emerging strategies. *Clin Radiol.* 2010;65(7):500–516.

37. Giepmans BN, Adams SR, Ellisman MH, Tsien RY. The fluorescent toolbox for assessing protein location and function. *Science.* 2006;312(5771):217–224.

38. Hoffman RM. The multiple uses of fluorescent proteins to visualize cancer in vivo. *Nat Rev Cancer.* 2005;5(10):796–806.

39. Adams KE, Ke S, Kwon S, et al. Comparison of visible and near-infrared wavelength-excitable fluorescent dyes for molecular imaging of cancer. *J Biomed Opt.* 2007;12(2):024017.

40. Hsu AR, Cai W, Veeravagu A, et al. Multimodality molecular imaging of glioblastoma growth inhibition with vasculature-targeting fusion toxin VEGF121/rGel. *J Nucl Med.* 2007;48(3):445–454.

41. Hama Y, Urano Y, Koyama Y, Choyke PL, Kobayashi H. Activatable fluorescent molecular imaging of peritoneal metastases following pretargeting with a biotinylated monoclonal antibody. *Cancer Res.* 2007;67(8):3809–3817.

42. Stummer W, Pichlmeyer U, Meinel T, Wiestler OD, Zanella F, Reulen HJ. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. *Lancet Oncol.* 2006;7(5):392–401.

43. Sevick-Muraca EM, Sharma R, Rasmussen JC, et al. Imaging of lymph flow in breast cancer patients after microdose administration of a near-infrared fluorophore: feasibility study. *Radiology.* 2008;246(3):734–741.

44. Loose D, Vermeersch H, De Vos F, Deron P, Slegers G, Van de Wiele C. Prognostic value of 99mTc-HYNIC annexin-V imaging in squamous cell carcinoma of the head and neck. *Eur J Nucl Med Mol Imaging.* 2008;35(1):47–52.

45. Belhocine T, Steinmetz N, Hustinx R, et al. Increased uptake of the apoptosis-imaging agent (99 m)Tc recombinant human annexin V in human tumors after one course of chemotherapy as a predictor of tumor response and patient prognosis. *Clin Cancer Res.* 2002;8(9):2766–2774.

46. Jennewein M, Lewis MA, Zhao D, et al. Vascular imaging of solid tumors in rats with a radioactive arsenic-labeled antibody that binds exposed phosphatidylserine. *Clin Cancer Res.* 2008;14(5):1377–1385.

47. Gerber DE, Hao G, Watkins L, et al. Tumor-specific targeting by bavituximab, a phosphatidylserine-targeting monoclonal antibody with vascular targeting and immune modulating properties, in lung cancer xenografts. *Am J Nucl Med Mol Imaging.* 2015;5(5):493–503.

48. Bulte JW, Kraitchman DL. Iron oxide MR contrast agents for molecular and cellular imaging. *NMR Biomed.* 2004;17(7):484–499.

49. Thorek DL, Chen AK, Czupryna J, Tsourkas A. Superparamagnetic iron oxide nanoparticle probes for molecular imaging. *Ann Biomed Eng.* 2006;34(1):23–38.

50. Yang L, Peng XH, Wang YA, et al. Receptor-targeted nanoparticles for in vivo imaging of breast cancer. *Clin Cancer Res.* 2009;15(14):4722–4732.

51. Zhou H, Stafford JH, Hallac RR, et al. Phosphatidylserine-targeted molecular imaging of tumor vascularity by magnetic resonance imaging. *J Biomed Nanotechnol.* 2014;10(5):846–855.

52. Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. *Nat Rev Drug Discov.* 2005;4(2):145–160.
53. Pastorino F, Brignole C, Marimpietri D, et al. Doxorubicin-loaded Fab' fragments of anti-disialoanglioside immunoliposomes selectively inhibit the growth and dissemination of human neuroblastoma in nude mice. *Cancer Res.* 2003;63(1):86–92.

54. Klibanov AL, Maruyama K, Torchilin VP, Huang L. Amphiphatic polyethyleneglycols effectively prolong the circulation time of liposomes. *FEBS Lett.* 1990;268(1):235–237.

55. Gabizon AA. Pegylated liposomal doxorubicin: metamorphosis of an old drug into a new form of chemotherapy. *Cancer Invest.* 2001;19(4):424–436.

56. Zhang L, Zhao D. Liposomal encapsulation enhances in vivo near infrared imaging of exposed phosphatidylserine in a mouse glioma model. *Molecules.* 2013;18(12):14613–14628.

57. Zhang L, Zhou H, Belzile O, Thorpe P, Zhao D. Phosphatidylserine-targeted bimodal liposomal nanoparticles for in vivo imaging of breast cancer in mice. *J Control Release.* 2014;183C:114–123.

58. Soman NR, Baldwin SL, Hu G, et al. Molecularly targeted nanocarriers deliver the cytolytic peptide melittin specifically to tumor cells in mice, reducing tumor growth. *J Clin Invest.* 2009;119(9):2830–2842.

59. Kirpotin DB, Drummond DC, Shao Y, et al. Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. *Cancer Res.* 2006;66(13):6732–6740.

60. Pastorino F, Brignole C, Marimpietri D, et al. Doxorubicin-loaded Fab’ fragments of anti-disialoanglioside immunoliposomes selectively inhibit the growth and dissemination of human neuroblastoma in nude mice. *Cancer Res.* 2003;63(1):86–92.

61. Blanco VM, Chu Z, Vallabhappurapu SD, et al. Phosphatidylserine-selective targeting and anticancer effects of SapC-DOPS nanovesicles on brain tumors. *Oncotarget.* 2014;5(16):7105–7118.

62. Wang et al. 2006;114(1):78–88.

63. Guo G, Gong K, Wohlfeld B, Hatanpaa KJ, Zhao D, Habib AA. Ligand-independent EGFR signaling. *Cancer Res.* 2015;75(17):3436–3441.

64. Ohtsuki S, Terasaki T. Contribution of carrier-mediated transport systems to the blood–brain barrier as a supporting and protecting interface for the brain; importance for CNS drug discovery and development. *Pharm Res.* 2007;24(9):1745–1758.

65. Pardridge WM. CNS drug design based on principles of blood–brain barrier transport. *J Neurochem.* 1998;70(5):1781–1792.

66. Hawkins BT, Davis TP. The blood–brain barrier/neurovascular unit in health and disease. *Pharmacol Rev.* 2005;57(2):173–185.

67. Fidler IJ, Yano S, Zhang RD, Fujimaki T, Bucana CD. The seed and soil hypothesis: vascularisation and brain metastases. *Lancet Oncol.* 2002;3(1):53–57.

68. Lockman PR, Mittapalli RK, Taskar KS, et al. Heterogeneous blood–tumor barrier permeability determines drug efficacy in experimental brain metastases of breast cancer. *Clin Cancer Res.* 2010;16(23):5664–5678.
87. Zhen Y, Zhao S, Li Q, Li Y, Kawamoto K. Arsenic trioxide-mediated Notch pathway inhibition depletes the cancer stem-like cell population in gliomas. Cancer Lett. 2010;292(1):64–72.

88. Kitange GJ, Carlson BL, Mladek AC, et al. Evaluation of MGMT promoter methylation status and correlation with temozolomide response in orthotopic glioblastoma xenograft model. J Neurooncol. 2009;92(1):23–31.

89. Kitange GJ, Carlson BL, Schroeder MA, et al. Induction of MGMT expression is associated with temozolomide resistance in glioblastoma xenografts. Neuro Oncol. 2009;11(3):281–291.

90. Blanco VM, Latif T, Chu Z, Qi X. Imaging and therapy of pancreatic cancer with phosphatidylserine-targeted nanovesicles. Transl Oncol. 2015;8(3):196–203.

91. Huang J, Li Y, Orza A, et al. Magnetic nanoparticle facilitated drug delivery for cancer therapy with targeted and image-guided approaches. Adv Funct Mater. 2016;26(22):3818–3836.

92. Penet MF, Krishnamachary B, Chen Z, Jin J, Bhujwalla ZM. Molecular imaging of the tumor microenvironment for precision medicine and theranostics. Adv Cancer Res. 2014;124:235–256.

93. Chen H, Pazicni S, Krett NL, et al. Coencapsulation of arsenic- and platinum-based drugs for targeted cancer treatment. Angew Chem Int Ed Engl. 2009;48(49):9295–9299.

94. Kim J, Aftab BT, Tang JY, et al. Itraconazole and arsenic trioxide inhibit Hedgehog pathway activation and tumor growth associated with acquired resistance to smoothened antagonists. Cancer Cell. 2013;23(1):23–34.

95. Pan D, Caruthers SD, Hu G, et al. Ligand-directed nanobialys as theranostic agent for drug delivery and manganese-based magnetic resonance imaging of vascular targets. J Am Chem Soc. 2008;130(29):9186–9187.

96. McDonagh BH, Singh G, Hak S, et al. L-DOPA-coated manganese oxide nanoparticles as dual MRI contrast agents and drug-delivery vehicles. Small. 2016;12(3):301–306.